Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.

Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G; HPV-010 Study Group.

Hum Vaccin. 2009 Oct;5(10):705-19. Epub 2009 Oct 14.

PMID:
19684472
2.

Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.

Schwarz TF.

Adv Ther. 2009 Nov;26(11):983-98. doi: 10.1007/s12325-009-0079-5. Epub 2009 Dec 18. Review.

PMID:
20024678
3.

Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.

Harper DM.

Public Health Genomics. 2009;12(5-6):319-30. doi: 10.1159/000214922. Epub 2009 Aug 11. Review.

PMID:
19684444
4.

Efficacy of human papillomavirus vaccines: a systematic quantitative review.

Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR.

Int J Gynecol Cancer. 2009 Oct;19(7):1166-76. doi: 10.1111/IGC.0b013e3181a3d100. Review.

PMID:
19823051
5.

Human papillomavirus vaccines.

Schmiedeskamp MR, Kockler DR.

Ann Pharmacother. 2006 Jul-Aug;40(7-8):1344-52. Epub 2006 Jul 18. Review.

PMID:
16849621
6.
7.

Current prophylactic HPV vaccines and gynecologic premalignancies.

Harper DM.

Curr Opin Obstet Gynecol. 2009 Dec;21(6):457-64. doi: 10.1097/GCO.0b013e328332c910. Review.

PMID:
19923989
8.

Measuring serum antibody to human papillomavirus following infection or vaccination.

Frazer IH.

Gynecol Oncol. 2010 Jun;118(1 Suppl):S8-11. doi: 10.1016/j.ygyno.2010.04.003. Review.

PMID:
20494221
9.

Long-term efficacy of human papillomavirus vaccination.

Ault KA.

Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S27-30. Review.

PMID:
17938016
10.

[HPV vaccination: principles, results and future perspectives].

Rouzier R, Uzan C, Collinet P.

J Gynecol Obstet Biol Reprod (Paris). 2007 Feb;36(1):13-8. Epub 2007 Jan 17. Review. French.

11.

[Human papillomavirus prophylactic vaccines: stakes and perspectives].

Hantz S, Alain S, Denis F.

Gynecol Obstet Fertil. 2006 Jul-Aug;34(7-8):647-55. Epub 2006 Jun 27. Review. French.

PMID:
16807045
12.

AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.

Schwarz TF.

Expert Rev Vaccines. 2008 Dec;7(10):1465-73. doi: 10.1586/14760584.7.10.1465. Review.

PMID:
19053203
13.

Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.

Broomall EM, Reynolds SM, Jacobson RM.

Postgrad Med. 2010 Mar;122(2):121-9. doi: 10.3810/pgm.2010.03.2129. Review.

PMID:
20203463
14.

Currently approved prophylactic HPV vaccines.

Harper DM.

Expert Rev Vaccines. 2009 Dec;8(12):1663-79. doi: 10.1586/erv.09.123. Review.

PMID:
19943762
15.

Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies.

Harper DM, Williams KB.

Discov Med. 2010 Jul;10(50):7-17. Review.

16.

Prospects and prejudices of human papillomavirus vaccines in India.

Das BC, Hussain S, Nasare V, Bharadwaj M.

Vaccine. 2008 May 23;26(22):2669-79. doi: 10.1016/j.vaccine.2008.03.056. Epub 2008 Apr 14. Review.

PMID:
18455843
17.

The prophylactic role for the human papillomavirus quadrivalent vaccine in males.

Yancey AM, Pitlick JM, Forinash AB.

Ann Pharmacother. 2010 Jul-Aug;44(7-8):1314-8. doi: 10.1345/aph.1P017. Epub 2010 May 25. Review.

PMID:
20501891
18.

Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).

Siddiqui MA, Perry CM.

Drugs. 2006;66(9):1263-71; discussion 1272-3. Review.

PMID:
16827602
20.

Supplemental Content

Support Center